IGF2BP2 Drives PTCL Growth and Immune Evasion, Offers Therapeutic Target
A new study identifies the RNA reader IGF2BP2 as a key oncogenic driver in peripheral T-cell lymphoma, promoting tumor growth and immune escape.
Stag2 Deficiency Reprograms GATA1 Binding, Driving Dyserythropoiesis in Myelodysplastic Syndromes
Loss of Stag2 alters chromatin accessibility, redirecting GATA1's transcriptional activity from erythroid to megakaryocyte pathways.
PIEZO1 Variant Reclassification Identifies Three Clinical Phenotypes in DHS1
A new framework reclassifies 1,000 variants of uncertain significance and links specific protein domains to iron overload risk.
Erythroid FGF23 Directly Inhibits Red Cell Production in Mouse Models
Local fibroblast growth factor 23 signaling in the bone marrow impairs erythropoiesis through FGFR1 activation and mitochondrial dysfunction.
Mosunetuzumab and Polatuzumab Vedotin Show High Response in Refractory MCL
A phase 2 trial reports a 78.6% complete response rate in patients with mantle cell lymphoma after Bruton tyrosine kinase inhibitor failure.
HIT Antibodies Undetectable by ELISA Activate Platelets in Mice and Humans
A prevalent subset of pathogenic antibodies in heparin-induced thrombocytopenia may be missed by standard immunoassays.